AstraZeneca has announced it will shell out £505m to the taxman to settle a
transfer pricing dispute spanning 15 years.
Under the agreement, AstraZeneca will pay the sum to resolve claims made by
the taxman for transactions made between 1996 and the end of 2010.
The movement of company assets or services from one part of a multinational
to another has long been a bone of contention for the taxman.
This is because of concerns the transactions are not carried out at arms
length, keeping tax revenues out of the UK’s coffers.
“As a result of this agreement, the joint referral of this issue to the UK
Tax Court by AstraZeneca and HMRC, as disclosed in the 2008 Annual Report, will
be withdrawn,” the FTSE 100 company added.
AstraZeneca had provided in its accounts for the outcome of this issue, “at
the heart of which are complex transfer price considerations that have taken
many years to resolve.”
The payment will be made by a first instalment of £350m in March 2010, and a
second final instalment of £155m in March 2011, AstraZeneca said.
Does Darwin's theory apply to taxation? Colin ponders...
The UK tax gap fell in 2014-15 to its lowest-ever level of 6.5%, revealed official statistics published today
Changes to the tax system is urged to support the growth of entrepreneurs, found a report from the Grant Thornton UK, the Institute of Directors, and the Prelude Group
The EC has been instructed to draft a European Union (EU) directive authorising an EU financial transaction tax, which would apply to ten of the EU’s 28 member states